| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47811903P | 2003-06-12 | 2003-06-12 |
| Publication Number | Publication Date |
|---|---|
| AR044774A1true AR044774A1 (en) | 2005-10-05 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040102008AAR044774A1 (en) | 2003-06-12 | 2004-06-10 | ATORVASTATIN PHARMACEUTICAL COMPOSITIONS |
| Country | Link |
|---|---|
| EP (1) | EP1635814A1 (en) |
| JP (1) | JP2006527260A (en) |
| KR (1) | KR100814218B1 (en) |
| CN (1) | CN100434069C (en) |
| AR (1) | AR044774A1 (en) |
| AU (1) | AU2004246868B2 (en) |
| BR (1) | BRPI0411344A (en) |
| CA (1) | CA2465565A1 (en) |
| CO (1) | CO5650230A2 (en) |
| MX (1) | MXPA05013281A (en) |
| NO (1) | NO20060022L (en) |
| NZ (1) | NZ543337A (en) |
| RU (1) | RU2332211C2 (en) |
| TW (1) | TW200503690A (en) |
| WO (1) | WO2004110431A1 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI94339C (en) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts |
| GB0613925D0 (en)* | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
| US20100196469A1 (en)* | 2007-06-25 | 2010-08-05 | Pharmathen S.A. | Pharmaceutical Formulation containing an HMG-COA Reductase Inhibitor and method for the preparation thereof |
| JP5492790B2 (en)* | 2008-02-27 | 2014-05-14 | トーメン メディカル アーゲー | Implant and manufacturing method thereof |
| JP5714492B2 (en)* | 2008-09-17 | 2015-05-07 | マイラン インコーポレイテッド | Granules, methods for their preparation, and pharmaceuticals containing them |
| RU2404767C1 (en)* | 2009-08-11 | 2010-11-27 | Закрытое Акционерное Общество "БИОКОМ" | Solid dosage form having hypolipidemic and hypocholesteremic activity, and method of its production |
| HUP1000299A2 (en) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostructured atorvastatin, its pharmaceutically acceptable salts and pharmaceutical compositions containing them and process for their preparation |
| EP2779999A2 (en) | 2011-11-15 | 2014-09-24 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical formulations comprising atorvastatin and glimepiride |
| UA117464C2 (en)* | 2012-11-02 | 2018-08-10 | Вертекс Фармасьютікалз Інкорпорейтед | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CFTR DISEASE-MEDIATED DISEASE REGULATOR |
| CN104069078B (en)* | 2014-05-22 | 2019-06-11 | 西藏九瑞健康股份有限公司 | Atorvastatin calcium pharmaceutical composition and preparation method thereof |
| EA202191301A1 (en)* | 2014-07-25 | 2021-11-30 | Новартис Аг | COMPOSITION OF TABLETS 2-FLUORO-N-METHYL-4- [7- (QUINOLIN-6-YLMETHYL) IMIDAZO [1,2-b] [1,2,4] TRIAZIN-2-YL] BENZAMIDE |
| KR101658350B1 (en)* | 2015-02-06 | 2016-09-30 | 경성대학교 산학협력단 | Pharmaceutical Composition For Treating Hyperlipidaemia |
| CN107427462B (en)* | 2015-03-12 | 2023-08-29 | 杜邦营养美国有限公司 | solid dispersion |
| EP3437646A4 (en) | 2016-03-31 | 2019-11-27 | Intercept Pharmaceuticals, Inc. | ORAL PREPARATION HAVING EXCEPTIONAL ABILITY TO ELUTE |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0680320T3 (en)* | 1993-01-19 | 1999-10-25 | Warner Lambert Co | Stable oral CI-981 preparation and method of preparation thereof |
| JPH06242003A (en)* | 1993-02-12 | 1994-09-02 | Nkk Corp | Grain size measuring method for alumina in steel |
| JP3014040B2 (en)* | 1996-10-30 | 2000-02-28 | 信久 川野 | Dietary fiber bread and method for producing the same |
| IL152179A (en)* | 2000-04-10 | 2009-06-15 | Teva Pharma | Stable pharmaceutical compositions containing 7-substituted-3,5- dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids |
| US6242003B1 (en)* | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
| EP1226818A1 (en)* | 2001-01-26 | 2002-07-31 | Pfizer Products Inc. | Pharmaceutical dosage forms with enhanced cohesive and compressibility properties |
| SI20848A (en)* | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Pharmaceutical formulation containing atorvastatin calcium |
| EP1291017A3 (en)* | 2001-09-10 | 2003-07-02 | Warner-Lambert Company | Use of statins to inhibit formation of osteoclasts |
| Publication number | Publication date |
|---|---|
| KR20060020666A (en) | 2006-03-06 |
| NZ543337A (en) | 2008-03-28 |
| WO2004110431A1 (en) | 2004-12-23 |
| CA2465565A1 (en) | 2004-12-12 |
| RU2332211C2 (en) | 2008-08-27 |
| NO20060022L (en) | 2006-01-03 |
| CN1805741A (en) | 2006-07-19 |
| JP2006527260A (en) | 2006-11-30 |
| TW200503690A (en) | 2005-02-01 |
| BRPI0411344A (en) | 2006-07-11 |
| KR100814218B1 (en) | 2008-03-17 |
| MXPA05013281A (en) | 2006-03-09 |
| CN100434069C (en) | 2008-11-19 |
| AU2004246868B2 (en) | 2008-01-17 |
| RU2005136745A (en) | 2006-07-27 |
| CO5650230A2 (en) | 2006-06-30 |
| EP1635814A1 (en) | 2006-03-22 |
| AU2004246868A1 (en) | 2004-12-23 |
| Publication | Publication Date | Title |
|---|---|---|
| AR044774A1 (en) | ATORVASTATIN PHARMACEUTICAL COMPOSITIONS | |
| AR044775A1 (en) | ATORVASTATIN PHARMACEUTICAL COMPOSITIONS | |
| DK1346041T3 (en) | Therapeutic agents and methods for their use in the treatment of an amyloidogenic disease | |
| LU93078I2 (en) | COMBIMETINIB, POSSIBLY IN ANY FORM PROTECTED BY THE BASIC PATENT, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS AND SOLVATES, IN PARTICULAR COBIMETINIB HEMIFUMARATE | |
| ES2124372T3 (en) | COMPOSITIONS OF PROLONGED RELEASE BASED ON MORPHINE. | |
| GT200100137A (en) | PRO-DRUGS OF 4-PHENYL-PYRIDINE DERIVATIVES. | |
| NO20060149L (en) | Pharmaceutical compounds of atorvastatin | |
| EA200901393A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING GESTAGENES AND / OR ESTROGENS AND 5 METHYL- (6S) -TETRAHYDROPHOLATE | |
| ATE360630T1 (en) | AZABICYCLIC HETEROCYCLES AS MODULATORS OF THE CANNABINOID RECEPTOR | |
| CR8102A (en) | DERIVATIVES OF PIRAZOLO-QUINAZOLINA, PROCEDURE FOR PREPARATION AND ITS USE AS QUINASE INHIBITORS | |
| GT200500098A (en) | NEW COMPOUNDS | |
| AR058780A1 (en) | IMIDAZOPIRAZINAS AS INHIBITORS OF CYCLINE-DEPENDENT KINASES | |
| UY30377A1 (en) | FUSIONATED TRICYCLE INHIBITORS OF SULFONAMIDE OF GAMA-SECRETASA | |
| PA8606201A1 (en) | PIRROLO DERIVATIVES [3,4-c) PIRAZOL ASSETS AS QUINASE INHIBITORS, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM | |
| AR060019A1 (en) | PHARMACEUTICAL COMPOSITION, PRODUCT AND TREATMENT METHOD FOR A COGNITIVE DISORDER AND USES OF AN ACETILCOLINESTERASE INHIBITOR AND A 5- HT6 ANTAGONIST IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A COGNITIVE DISORDER | |
| BRPI0509074A (en) | pharmaceutical compositions comprising thyroid receptor agonists | |
| AR048336A1 (en) | HYDROCLORIDE OF (4- (5-AMINOMETIL-2-FLUORO-PHENYL) -PIPERIDIN-1-IL) - (4-BROMO-3-METHYL-5-PROPOXI-TIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE MASTOCYT TRIPTASE | |
| MX2024013019A (en) | Heteroaryl compounds for the treatment of pain | |
| AR018162A1 (en) | SUBSTITUTED PIRROLS, PHARMACEUTICAL COMPOSITION AND THE USE OF THEM FOR THE PREPARATION OF SUCH PHARMACEUTICAL COMPOSITION | |
| AR030140A1 (en) | COMPOSITIONS DERIVED FROM 2-PYRIDINAMINE AND RELATED METHODS | |
| SE0401655D0 (en) | New compounds | |
| AR026911A1 (en) | PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF TUMOR AFFECTIONS | |
| DK1784173T3 (en) | Pharmaceutical composition for the prevention and treatment of metabolic bone disorders containing alpha-arylmethoxyacrylate derivatives | |
| EA200401100A1 (en) | 1α-FTOR-25-HYDROXY-16,23E-DIEN-26,27-BISHOMO-20-EPICHOLOCALTI-SPHEROL AND ITS APPLICATION FOR TREATMENT | |
| AR040121A1 (en) | A COMBINATION OF NMDA ANTAGONIST AND INHIBITORS OF ACETILCOLINE ESTERASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |